By Ethan Covey
Use of the new fecal microbiota products following antibiotics in the treatment of recurrent Clostridioides difficile infection (rCDI) resulted in low rates of CDI recurrence.
The products have been found to be safe, with minimal, nonserious adverse events (Am J Health Syst Pharm 2024 Mar 12. https://doi.org/10.1093/ajhp/zxae066). The two approved products are fecal microbiota, live-jslm (Rebyota, Ferring Pharmaceuticals) and fecal microbiota (Vowst, Seres Therapeutics).
“At a